Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Day One Biopharmaceuticals (DAWN) over the last 6 years, with Dec 2024 value amounting to $203.3 million.

  • Day One Biopharmaceuticals' Cash from Financing Activities fell 42.33% to $748,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $204.0 million, marking a year-over-year increase of 9816.92%. This contributed to the annual value of $203.3 million for FY2024, which is 23.96% up from last year.
  • Day One Biopharmaceuticals' Cash from Financing Activities amounted to $203.3 million in FY2024, which was up 23.96% from $164.0 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Cash from Financing Activities peaked at $297.1 million during FY2021, and registered a low of $30.0 million during FY2020.
  • In the last 3 years, Day One Biopharmaceuticals' Cash from Financing Activities had a median value of $165.9 million in 2022 and averaged $177.7 million.
  • In the last 5 years, Day One Biopharmaceuticals' Cash from Financing Activities skyrocketed by 891.16% in 2021 and then slumped by 44.16% in 2022.
  • Day One Biopharmaceuticals' Cash from Financing Activities (Yearly) stood at $30.0 million in 2020, then spiked by 891.16% to $297.1 million in 2021, then plummeted by 44.16% to $165.9 million in 2022, then decreased by 1.15% to $164.0 million in 2023, then increased by 23.96% to $203.3 million in 2024.